Selank
Research OnlyAlso known as: TP-7, Selanc, Threonyl-Lysyl-Prolyl-Arginyl-Prolyl-Glycyl-Proline
A synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, developed by Russian researchers and approved in Russia since 2009 for anxiety and neurasthenia. Demonstrates anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or dependence liability. Extensive Russian clinical research supports efficacy, though Western independent replication remains limited.
Research Statistics
Russian-origin anxiolytic approved in Russia since 2009. Limited independent Western replication (some Ukrainian and European preclinical work). Mechanism via tuftsin backbone with GABA/BDNF modulation is supported but primarily from Russian studies.
Research Dossier
Overview
What is Selank and what does the research say?
Mechanism of Action
Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension that confers CNS activity and enhanced stability. Unlike traditional anxiolytics that directly bind receptors, Selank works primarily through gene expression modulation, producing sustained effects without tolerance or dependence.
How It Works (Simplified)
Modulates gene expression of GABA-A receptor subunits, enhancing inhibitory neurotransmission for calming effects without the sedation or dependence of benzodiazepines.
Inhibits enzymes that degrade enkephalins, allowing your natural “feel-good” opioids to work longer for mood elevation and stress resilience.
Increases brain-derived neurotrophic factor in the hippocampus and frontal cortex, supporting memory consolidation, learning, and neuroplasticity.
Modulates 5-HT1A and 5-HT2A receptor expression, contributing to mood stabilization and anxiolytic effects similar to buspirone but at the transcriptional level.
Scientific Pathways
GABAergic System Modulation (Primary Anxiolytic Mechanism)
Selank → Gene expression modulation
↓
GABA-A receptor subunit changes (alpha, beta, gamma)
↓
├── Enhanced GABAergic neurotransmission
├── Reduced neuronal excitability
└── Anxiolytic effect WITHOUT benzodiazepine-like sedation/toleranceEnkephalinergic System (Mood & Well-being)
Enkephalin-degrading enzymes (aminopeptidases)
↓ (Selank inhibition)
Elevated endogenous enkephalin levels
↓
├── Mu and delta opioid receptor activation
├── Natural mood enhancement
└── Stress resilience without exogenous opioid risksNeurotrophic Pathway (Cognitive Enhancement)
Selank → Frontal cortex & hippocampus
↓
BDNF mRNA upregulation
↓
├── Neuroplasticity enhancement
├── Memory consolidation improvement
└── Stress-induced cognitive decline protectionKey Research: Zozulia AA et al. (2008) demonstrated significant anxiolytic efficacy in 62 GAD patients without sedation. PMID:18577768
Important Limitations
- Most clinical research originates from Russian institutions with limited Western replication
- Approved in Russia (2009) but not by FDA, EMA, or other Western regulatory agencies
- Many primary studies published only in Russian, limiting accessibility
- Long-term effects beyond 14-day treatment courses less well characterized
- Gene expression mechanism means onset takes days rather than minutes
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Gene expression modulation begins. Unlike fast-acting anxiolytics, Selank works through transcriptional changes requiring time for protein synthesis. Minimal acute effects expected as GABA receptor subunit genes begin modulation.
Initial anxiolytic effects may emerge as GABA-A receptor subunit changes accumulate. Russian clinical protocols typically use 14-day courses. Enkephalin levels begin rising due to aminopeptidase inhibition.
Clinical trials show significant HAM-A score reductions by end of 14-day treatment. BDNF upregulation contributing to cognitive improvements. Mood stabilization from serotonin receptor modulation.
Sustained anxiolytic effects with continued administration. No tolerance development observed in clinical studies. Cognitive benefits become more apparent with improved memory consolidation.
Effects may persist beyond treatment cessation due to gene expression changes. No withdrawal symptoms reported, distinguishing Selank from benzodiazepines. Duration of post-treatment benefit not well characterized.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Selank product quality
Good Signs (7 indicators)
Warning Signs (6 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Selank with other peptides. Based on published research and mechanistic considerations.
Semax
SynergisticBoth Russian regulatory peptides with complementary effects - Selank provides anxiolysis while Semax enhances cognition. Often used together in Russian clinical practice.
Epithalon
CompatibleBoth Russian bioregulator peptides with distinct targets - Selank for anxiety via GABA modulation, epithalon for longevity via telomerase. No known interactions.
Thymosin-Alpha-1
CompatibleBoth have immunomodulatory properties - Selank via tuftsin backbone, Ta1 as primary function. May have complementary immune effects.
BPC-157
CompatibleDifferent primary targets - Selank for CNS anxiolysis, BPC-157 for tissue repair. BPC-157's reported CNS effects may complement Selank's anxiolytic action.
LL-37
CompatibleSelank retains immunomodulatory properties from tuftsin backbone; LL-37 provides direct antimicrobial effects. Different immune modulation pathways.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Selank
Selank Calculators
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.